Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Ağustos 27, 2025
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
OCT changes with low-level red light therapy for myopia in children
Ağustos 26, 2025
Alcon presenting at APACRS 2025
Ağustos 21, 2025
Breaking News
Popular Now
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase…
FDA approves Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%. | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine…
Collaborate With Us
Join forces with Ophthalmology News to reach a global community of eye care professionals. Whether you want to contribute an article, share research, or explore partnership opportunities, we’d love to hear from you.
Editor Choice
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase…
FDA approves Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%. | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine…
The Art and Science of Presbyopia Correction: Navigating the IOL Patient Journey | Ophthalmology Times
Presbyopia-correcting IOLs have undergone a dramatic transformation in recent years. The once-limited…
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada | Ophthalmology Times
(Image Credit: AdobeStock/platinumArt) Health Canada has approved Celltrion’s Eydenzelt, a biosimilar referencing…
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ | Ophthalmology Times
(Image Credit: AdobeStock/Rawf8) LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted…
Phase 1 trial confirms safety and tolerability of Huons’ dry eye therapy | Ophthalmology Times
(Image Credit: AdobeStock) Huons Co, a pharmaceutical subsidiary of Huons Group, received…
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/doucefleur) Belite Bio has released topline results from the global…
Worth Reading
Meeting expectations with evolving technology
Ağustos 26, 2025
/ Patient Education, Research & Studies, Technology & Innovation, Treatments & Surgery
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Ağustos 26, 2025
/ Industry News, Patient Education, Research & Studies, Treatments & Surgery
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Ağustos 26, 2025
/ Patient Education, Research & Studies
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
/ Patient Education, Research & Studies, Treatments & Surgery
Subscribe Now
Enter your email address below and subscribe to our newsletter